Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while projecting a positive outlook for the company’s future in 2026 and beyond.

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for the past year. On March 4, ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Moderna on Thursday said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine ...